What Analysts Are Saying About Sarepta Therapeutics Stock
What Analysts Are Saying About Sarepta Therapeutics Stock
分析師對Sarepta Therapeutics股票的看法
In the latest quarter, 14 analysts provided ratings for Sarepta Therapeutics (NASDAQ:SRPT), showcasing a mix of bullish and bearish perspectives.
在最近一個季度中，14位分析師爲Sarepta Therapeutics（納斯達克股票代碼：SRPT）提供了評級，顯示了看漲和看跌的觀點。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表簡要概述了分析師最近的評級，提供了對過去30天情緒變化的見解，並與前幾個月進行了比較以獲得整體視角。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $157.21, with a high estimate of $224.00 and a low estimate of $128.00. Observing a 8.14% increase, the current average has risen from the previous average price target of $145.38.
分析師對12個月目標股價的評估提供了更多見解，顯示平均目標價爲157.21美元，最高估計爲224.00美元，低估值爲128.00美元。目前的平均價格上漲了8.14％，已從之前的平均目標價145.38美元上漲。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析師評級：深度分析
An...
對...
登入免費觀看全文
登入/註冊